Onconomics Plus RGCC
Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of the extensive tests provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used by clinicians to design personalised and targeted cancer therapies with the highest chances of success.
Purpose of the test
Purpose of the test
Onconomics Plus RGCC assesses the effectiveness (chemosensitivity) of specific anti-cancer drugs and targeted therapies on a sample provided by the patient.
Cancer is caused when cells mutate and spread. The key to cancer treatment is identifying and inhibiting (or stopping) these cells from multiplying and spreading.
Scientists performing the Onconomics Plus RGCC expose samples of a patient’s cells to cancer treatments and therapies, recording how effective they are at targeting the cancer cells. Scientists are searching for cytotoxic drugs (those which effectively kill cancer cells).
Onconomics Plus RGCC can be used by clinicians to identify the combination of cancer treatments that has the greatest chance of success. It’s the very definition of personalised cancer treatment.
Useful information
Useful information
Onconomics Plus RGCC assesses the chemosensitivity of anti-cancer drugs at treating a patient’s cancer. Because we are all different, our response to treatments can differ too. Onconomics Plus RGCC uses gene expression viability assays to test how the cells respond to specific cancer treatments. Scientists are searching for cytotoxic drugs (those which effectively kill cancer cells).
The results of Onconomics Plus RGCC provide detailed information into how effective a specific therapy or drug will be in treating cancer. The results must be interpreted by a clinician, who will assess the thresholds:
- Over 80% cytotoxicity: The drug targets more than 80% of living cells in the sample, therefore it shows sensitivity.
- Between 35% and 80%: The drug targets 35-80% of living cells in the sample, therefore it shows moderate sensitivity.
- Below 35%: The drug targeted less than 35% of living cells in the sample; therefore, the substance is ineffective. This is known as resistance.
Onconomics Plus RGCC requires 15-25 ml of whole (peripheral) blood, to be sent in a liquid preservative in a 50ml volume Falcon tube. Tissue samples require a minimum of 400mg, sent in the vial provided.
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on how to access, perform or analyse the results of the Onconomics Plus test, then get in touch today.